Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 As filed with the Securities and Exchange Commission on September 29, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION MEDICUS PHARMA LTD. (Exact name of Registrant as specified in its charter) ______________________________ (State or other jurisdiction of incorporation or organization) Ontario, Canada 2834 98-1778211 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Id ...

As filed with the Securities and Exchange Commission on September 29, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICUS PHARMA LTD. (Exact name of Registrant as specified in its charter) ______________________________ (State or other jurisdiction of incorporation or organization) Ontario, Canada 2834 98-1778211 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Id ...

Core Insights - Proactive is a financial news and online broadcast organization that provides fast, accessible, and actionable business and finance news to a global investment audience [2][3] - The company specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's editorial and broadcast operations are managed by a seasoned team, ensuring quality control and content production across multiple global locations [1][2] Company Operations - Proactive operates with a team of experienced news journalists across key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - The organization produces approximately 50,000 pieces of real-time news, feature articles, and filmed interviews annually [1] - Proactive employs both human content creators and technology to enhance workflows, ensuring a blend of expertise and innovation in content production [4][5] Content Focus - The news team at Proactive delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] - The company emphasizes the importance of human editing and authorship in its content production, even while utilizing automation and software tools [5]

Core Insights - The FDA has approved the Company to pursue the 505(b)(2) regulatory pathway for a non-invasive treatment of basal cell carcinoma (BCC) using dissolvable Doxorubicin-containing Microneedle arrays (D-MNA) [1] - The potential market opportunity for this treatment is estimated at approximately $2 billion [1] - The Company aims to complete patient recruitment for the SKNJCT-003 trial by the end of Q4 2025 and plans to request End-of-Phase 2 (EOP2) with the FDA in Q1 2026 [1] Company Developments - Medicus Pharma Ltd. is focused on advancing clinical development programs for novel and potentially disruptive therapeutic assets [1] - Positive feedback was received from a Type C meeting with the FDA, indicating a favorable regulatory outlook for the Company's product [1]

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)September 24, 2025 9:26 AM EDT | Source: Reportable, Inc. Dallas, Texas--(Newsfile Corp. - September 24, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX): Stonegate Capital Partners initiates their coverage on Medicus Pharma Ltd. (NASDAQ: MDCX). Medicus advanced several strategic initiatives in 2Q25 as it builds a diversified portfolio of clinical and pre-clinical assets. The Company completed the acquisition of Antev Limited ...

Core Insights - The company is advancing its novel Doxorubicin containing Microneedle Array (D-MNA) treatment for non-invasive basal cell carcinoma (BCC) and developing Teverelix, a next-generation GnRH Antagonist for Acute Urinary Retention (AURr) and high cardiovascular risk prostate cancer [1] Market Opportunity - D-MNA and Teverelix collectively represent approximately $8 billion in potential market opportunity [1] Company Activities - The company will participate in a live fireside chat on September 29, 2025, hosted by Kumaraguru (Kumar) Raja, Ph.D. [1]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - The company plans to utilize the proceeds from a recent purchase agreement to expedite the development of Teverelix, a next-generation GnRH Antagonist targeting Acute Urinary Retention (AURr) and high cardiovascular risk Prostate Cancer [1] - Teverelix represents a significant market opportunity, estimated at approximately $6 billion [1] Company Developments - Medicus Pharma Ltd. has entered into a purchase agreement with YA II PL, Ltd. to support its clinical development programs [1] - The focus of the company is on advancing novel and disruptive therapeutic assets within the biotech and life sciences sector [1]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers key finance and investing hubs globally, including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers news and insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] - Proactive adopts technology to enhance workflows, utilizing decades of expertise and experience [4] - Automation and software tools, including generative AI, are occasionally used, but all content is edited and authored by humans [5]